Novel SN38 derivative-based liposome as anticancer prodrug: an in vitro and in vivo study
Chan Wu,1,* Yang Zhang,1,2,* Daoqiu Yang,3,* Jinfeng Zhang,4 Juanjuan Ma,1 Dan Cheng,1 Jianming Chen,1,5 Li Deng1 1Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai 200433, People’s Republic of China; 2Department of Pharmacy, Shanghai Tenth Peopl...
Main Authors: | Wu C, Zhang Y, Yang D, Zhang J, Ma J, Cheng D, Chen J, Deng L |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-12-01
|
Series: | International Journal of Nanomedicine |
Subjects: | |
Online Access: | https://www.dovepress.com/novel-sn38-derivative-based-liposome-as-anticancer-prodrug-an-in-vitro-peer-reviewed-article-IJN |
Similar Items
-
Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy
by: Xing J, et al.
Published: (2019-07-01) -
PEGylation of lipophilic SN38 prodrug with DSPE-mPEG2000 versus cremophor EL: comparative study for intravenous chemotherapy
by: Jun Zeng, et al.
Published: (2019-01-01) -
Liposomal codelivery of an SN38 prodrug and a survivin siRNA for tumor therapy
by: Bi Y, et al.
Published: (2018-10-01) -
Synthesis and Biological Evaluation of Novel 10-Substituted-7-ethyl-10-hydroxycamptothecin (SN-38) Prodrugs
by: Mo Zhou, et al.
Published: (2014-11-01) -
SN38-loaded <100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: in vitro and in vivo study
by: Fang YP, et al.
Published: (2018-05-01)